Skip to main content
. 2021 Feb 5;268(9):3105–3115. doi: 10.1007/s00415-021-10425-9

Table 2.

Characteristics of patients included in individual patient data pooled analysis

Demographics (n = 98)
 Age - Median (IQR) 60 (53–67)
 Male % (95% CI) 64% (54–73.7%)
Vascular risk factors: (n = 91) N (%, 95% CI)
 Hypertension 48 (53%, 42.0–63.3%)
 Diabetes 26 (29%, 19.6–39.0%)
 Dyslipidaemia 15 (16%, 9.5–25.7%)
 Smoking 10 (11%, 5.4–19.3%)
 High body mass index 10 (11%, 5.4–19.3%)
 Atrial fibrillation 3 (3%, 0.7–9.3%)
 Ischemic heart disease 3 (3%, 0.7–9.3%)
 Alcohol 2 (2%, 0.3–7.7%)
 No previous medical history 18 (20%, 12.1–29.5%)
Intracerebral haemorrhage characteristics N (%, 95% CI)
 Location (n = 96)
  Lobar 64 (67%, 56.3–76.0%)
  Non-lobar (deep or infratentorial) 28 (29%, 20.3–39.3%)
  Mixed (lobar and non-lobar) 4 (4%, 1.15–10.3%)
 Multifocality (n = 91)
  Multifocal 33 (36%, 26.4–47.0%)
  Focal 58 (64%, 53.0–73.6%)
 Aetiology (n = 98)
  Coagulopathy 50 (51%, 40.7–61.3%)
  Hypertensive arteriopathy 11 (11%, 5.7–19.2%)
  Cerebral amyloid angiopathy 1 (1%, 0.0–5.6%)
  Macrovascular causes (*) 3 (3%, 0.6–8.7%)
  Cerebral venous thrombosis 1 (1%, 0.0–5.6%)
  Moya-Moya disease 1 (1%, 0.0–5.6%)
  Undetermined 31 (32%, 22.6–41.8%)
Anticoagulation (n = 91) N (%, 95% CI)
 Therapeutic unfractionated heparin 36 (40%, 29.5–50.4%)
 Therapeutic low molecular weight heparin 14 (15%, 8.7–24.5%)
 Prophylactic low molecular weight heparin 12 (13%, 7.0–21.9%)
 Warfarin 3 (3%, 0.7–9.3%)
 No anticoagulation 26 (29%, 19.6–39.0%)
COVID-19 N (%, 95% CI)
 Prior symptoms (n = 92)
  Prior COVID-19 symptoms 71 (77%, 67.3–85.3%)
  No prior COVID-19 symptoms 21 (23%, 14.7–32.8%)
 Days since COVID-19 symptoms (n = 68)
  Median, IQR 15 (5–20)
 Severity (n = 97)
  Critical 77 (79%, 70.0–86.9%)
  Severe 4 (4%, 1.1–10.2%)
  Moderate 9 (9%, 4.3–16.9%)
  Mild 2 (2%, 0.3–7.3%)
  Asymptomatic 5 (5%, 1.7–11.6%)
  ECMO (n = 98) 20 (21%, 12.9–29.8%)
 Outcome (n = 98)
  Deceased 53 (54%, 43.7–64.2%)
  Critically ill 18 (18%, 11.3–27.5%)
  Discharged to rehabilitation unit or home 27 (28%, 19.0–37.5%)
Coagulability markers Median, IQR
 D-Dimer (μg/L) (n = 64) 3387 (1745–5670)
 Fibrinogen (g/L): (n = 42) 5 (3.6–6.5)
 aPTT (s) (n = 36) 32 (25–59.5)
 PTT (s) (n = 21) 64 (41.6–89.3)
 INR (n = 45) 1.2 (1.1–1.5)
 Prothrombin time (s) (n = 28) 12.8 (11.7–15.7)
 Platelet count (/ mm3) (n = 72) 211 (143, 288.5 k)
 CRP (mg/L) (n = 57) 74 (13–130)
 Serum ferritin (μg/L) (n = 20) 1554 (983–2289)

*Macrovascular causes (aneurysm, arteriovenous malformation, cavernous malformation)

ECMO extracorporeal membrane oxygenation, aPTT activated partial thromboplastin time, PTT prothrombin time, INR international normalised ratio, CRP C-reactive protein